Subtype
Soft Tissue Neoplasm of Uncertain Differentiation
CI-CAN-00001532Explore in graph →
Non-malignant74 active trials2 approved drugs38 evidence items
- NCIt
- C7148
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001532Explore in graph →
Clinical trials
241 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT06094101 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)(PerVision) | recruiting | Phase 1 / Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04332874 | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548177 | Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma | recruiting | Phase 2 | 33 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 66 | National Cancer Institute LAOUNKNOWN | 2 | Apr 21, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07502716 | Compassionate Use of Ubamatamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT06453642 | Evaluation of a Simple-Prep Controlled Embolic(GPX) | active not recruiting | N/A | 114 | Fluidx Medical Technology, Inc.INDUSTRY | 3 | Mar 30, 2026 | clinicaltrials |
| NCT06789081 | GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02) | active not recruiting | Early Phase 1 | 1 | AHS Cancer Control AlbertaOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04008238 | Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients(PIPER) | completed | N/A | 29 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03016819 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)(APROMISS) | recruiting | Phase 3 | 325 | Advenchen Laboratories, LLCINDUSTRY | 5 | Feb 25, 2026 | clinicaltrials |
| NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients(PANTHR-S) | recruiting | — | 800 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas | recruiting | Phase 1 / Phase 2 | 63 | David S Shulman, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03304678 | Discovery of Sirolimus Sensitive Biomarkers in Blood | completed | Phase 2 | 33 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03967834 | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group(MIRAS) | recruiting | N/A | 400 | Institut Claudius RegaudOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT01391962 | Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT07169344 | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma(PROSARC-1) | recruiting | Phase 2 | 110 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07173972 | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.(PROSARC-2) | recruiting | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT01231906 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | completed | Phase 3 | 642 | Children's Oncology GroupNETWORK | 6 | Jan 23, 2026 | clinicaltrials |
| NCT06160310 | Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) | recruiting | — | 300 | David M. RitterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | recruiting | Phase 1 | 25 | Baylor College of MedicineOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05467397 | Feasibility of [11C]Acetate-PET in LAM and TSC | active not recruiting | Phase 1 / Phase 2 | 7 | Brigham and Women's HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06889168 | Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)(LAMP-2) | recruiting | Phase 1 | 20 | Columbia UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04690374 | Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor | recruiting | — | 250 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | recruiting | Phase 1 | 15 | Immatics US, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04204941 | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | terminated | Phase 1 | 25 | Epizyme, Inc.INDUSTRY | 4 | Jan 7, 2026 | clinicaltrials |
| NCT06942442 | A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma | recruiting | Phase 2 | 47 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07304856 | Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex | recruiting | — | 80 | University of MilanOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT00668291 | Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC)(EVACARNEY) | completed | — | 133 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03099681 | An Observational Study on Epithelioid Sarcoma(EPISObs) | recruiting | — | 100 | Italian Sarcoma GroupNETWORK | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07153887 | Vebreltinib for Advanced or Metastatic CCS | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06827886 | GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma(GCAR1) | completed | Early Phase 1 | 1 | AHS Cancer Control AlbertaOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | withdrawn | Phase 2 | 0 | Situs Cancer Research CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06813417 | CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma(SPS-Q2) | active not recruiting | Early Phase 1 | 1 | University of CalgaryOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04965753 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | terminated | Phase 1 | 55 | Foghorn Therapeutics Inc.INDUSTRY | 4 | Mar 4, 2025 | clinicaltrials |
Data updated 22 days agoSource updated May 15, 2026source: clinicaltrials